Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Unity Biotechnology Inc (UBX)
NASDAQ:UBX
Holding UBX?
Track your performance easily
UBX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.22 - $2.50
Previous Close$1.45
Volume61.92K
Average Volume (3M)41.30K
Market Cap
$24.43M
Enterprise Value$12.10M
Total Cash (Recent Filing)$33.98M
Total Debt (Recent Filing)$21.66M
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Nov 06, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.98
Shares Outstanding16,847,622
10 Day Avg. Volume35,569
30 Day Avg. Volume41,295
Standard Deviation0.23
R-Squared0.04
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.24
Price to Sales (P/S)8.30
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.09
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.46
Forecast
1Y Price Target
$8.00Price Target Upside451.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Unity Biotechnology News
PremiumCompany Announcements
Unity Biotechnology Focuses on Promising DME Treatment
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
UBX FAQ
What was Unity Biotechnology Inc’s price range in the past 12 months?
Unity Biotechnology Inc lowest stock price was $1.22 and its highest was $2.50 in the past 12 months.
What is Unity Biotechnology Inc’s market cap?
Currently, no data Available
When is Unity Biotechnology Inc’s upcoming earnings report date?
Unity Biotechnology Inc’s upcoming earnings report date is Nov 06, 2024 which is 20 days ago.
How were Unity Biotechnology Inc’s earnings last quarter?
Unity Biotechnology Inc released its earnings results on Aug 06, 2024. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.152.
Is Unity Biotechnology Inc overvalued?
According to Wall Street analysts Unity Biotechnology Inc’s price is currently Undervalued.
Does Unity Biotechnology Inc pay dividends?
Unity Biotechnology Inc does not currently pay dividends.
What is Unity Biotechnology Inc’s EPS estimate?
Unity Biotechnology Inc’s EPS estimate is -$0.4.
How many shares outstanding does Unity Biotechnology Inc have?
Unity Biotechnology Inc has 16,847,622 shares outstanding.
What happened to Unity Biotechnology Inc’s price movement after its last earnings report?
Unity Biotechnology Inc reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went up 1.439%.
Which hedge fund is a major shareholder of Unity Biotechnology Inc?
Among the largest hedge funds holding Unity Biotechnology Inc’s share is Invus Financial Advisors, LLC. It holds Unity Biotechnology Inc’s shares valued at N/A.
---
Unity Biotechnology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (451.72% Upside)
$8.00 (451.72% Upside)
Blogger Sentiment
Bullish
UBX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 109.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.29%
12-Months-Change
Fundamentals
Return on Equity
-88.77%
Trailing 12-Months
Asset Growth
-47.01%
Trailing 12-Months
Company Description
Unity Biotechnology Inc
Unity Biotechnology, Inc. operates as a biotechnology company engaged in the research and development of therapeutics to extend the human health span. The company was founded by Nathaniel David, Jan van Deursen, Judith Campisi and Daohong Zhou in March 2009 and is headquartered in Brisbane, CA.
---
UBX Stock 12 Month Forecast
Average Price Target
$8.00
▲(451.72% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Bioxcel Therapeutics
―
Cellectar Biosciences
―
Fate Therapeutics
―
Best Analysts Covering UBX
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-34.60%
upgraded a buy rating a year ago
Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -34.60% per trade.
---